Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

DNA TOPOISOMERASES

1985 • 1,524 citations

Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide

1999 • 1,394 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104

2002 • 671 citations

Small-cell lung cancer

2005 • 494 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

1992 • 443 citations

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1998 • 176 citations

Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.

1996 • 132 citations

Activity of docetaxel (Taxotere) in small cell lung cancer

1994 • 130 citations

Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.

1988 • 125 citations

A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex

1998 • 107 citations

Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells

1998 • 100 citations

Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds

1987 • 86 citations

Phase I–II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer

2005 • 86 citations

Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts

1989 • 83 citations

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients

1993 • 75 citations

Phase II Study of Vinorelbine in Heavily Previously Treated Small Cell Lung Cancer

1996 • 74 citations

Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs

1998 • 72 citations

Single-agent gemcitabine in patients with resistant small-cell lung cancer

2001 • 65 citations

Recurrent small cell lung cancer: Update

2003 • 46 citations

Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

2006 • 34 citations

55 Phase II study of amrubicin (SM-5887), a novel 9-amino-anthracycline, in previously untreated patients with extensive-stage small-cell lung cancer (ES-SCLC): A trial of the west Japan lung cancer group

1997 • 23 citations

Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of a 5-year follow-up

1990 • 16 citations

Second-line treatment of small-cell lung cancer. The case for systemic chemotherapy.

2003 • 14 citations